Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genetic Tech Spn ADR (NQ: GENE )

0.7650 UNCHANGED
Last Price Updated: 3:59 PM EDT, Oct 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Genetic Tech Spn ADR

< Previous 1 2 Next >
Genetic Technologies building pathway to profitability
Genetic Technologies Ltd (ASX:GTG; NASDAQ:GENE) CEO Simon Morriss tells Proactive the focus over the next 18 years is putting the pathway in place to see the business on track to profitability. GTG... 
Via TheNewswire.com
GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital Network
From Genetic Technologies Ltd
Via GlobeNewswire
Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report® on Bloomberg TV
Via ACCESSWIRE
Breakthrough: GeneType for Pancreatic Cancer, Melanoma, and Atrial Fibrillation Cleared for Australian Release
From Genetic Technologies Ltd
Via GlobeNewswire
GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner
Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice 
From Genetic Technologies Ltd
Via GlobeNewswire
Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TV
From Genetic Technologies Ltd
Via GlobeNewswire
Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
Via ACCESSWIRE
Annual Results – Momentum Building on our Commercial Plans
From Genetic Technologies Ltd
Via GlobeNewswire
Genetic Technologies Limited Announces Updated Investor Presentation
From Genetic Technologies Ltd
Via GlobeNewswire
Quarterly Activities Update: Encouraging Growth for geneType Commercial Test Volume
From Genetic Technologies Ltd
Via GlobeNewswire
Genetic Technologies Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
From Genetic Technologies Ltd
Via GlobeNewswire
GeneType featured on U.S. National TV to raise Breast Cancer Awareness
From Genetic Technologies Ltd
Via GlobeNewswire
New Publication Validates geneType for Melanoma Risk Assessment
From Genetic Technologies Ltd
Via GlobeNewswire
Quarterly Business Update – March 2023
Driving growth, Expanded Multi-Test Panel and Publications Validating Clinical Utility of geneType 
From Genetic Technologies Ltd
Via GlobeNewswire
Publication Validates geneType Prostate Cancer Risk Test
From Genetic Technologies Ltd
Via GlobeNewswire
GeneType Multi-Risk Test now includes Melanoma, Pancreatic Cancer & Atrial Fibrillation
From Genetic Technologies Ltd
Via GlobeNewswire
Back-to-back Studies Validate geneType Breast Cancer Risk Test
From Genetic Technologies Ltd
Via GlobeNewswire
New Publication Highlights geneType’s Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification
From Genetic Technologies Ltd
Via GlobeNewswire
Genetic Technologies Announces $5 Million Registered Direct Offering
From Genetic Technologies Ltd
Via GlobeNewswire
GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer
From Genetic Technologies Ltd
Via GlobeNewswire
GTG to form Strategic Alliance with global testing leader QIAGEN
From Genetic Technologies Ltd
Via GlobeNewswire
Quarterly Business Update – December 2022; Sixth Consecutive Quarter of Growth
From Genetic Technologies Ltd
Via GlobeNewswire
Genetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer Symposium
From Genetic Technologies Ltd
Via GlobeNewswire
Genetic Technologies Provides Business Update
From Genetic Technologies Ltd
Via GlobeNewswire
GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes
From Genetic Technologies Ltd
Via GlobeNewswire
Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease
From Genetic Technologies Ltd
Via GlobeNewswire
Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention
From Genetic Technologies Ltd
Via GlobeNewswire
Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer
From Genetic Technologies Ltd
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.